The CHMP, Europe's equivalent of an FDA advisory committee that almost always gets its way, recently issues a slew of recommendations for the EU's health agency. One of the biggest winners was Eli Lilly (NYSE: LLY).
Struggling with the patent cliff, Lilly is in the process of reinventing itself as a diabetes fighting powerhouse. One of the cornerstone franchises helping power that transformation is a less expensive generic version of the $8 billion blockbuster Lantus. Sanofi's (NYSE: SNY) insulin is one of the world's top selling drugs, but it will have a fight on its hands from Eli Lilly's Abasria. As the only biosimilar Eli Lilly will be able to undercut Sanofi, but at the same time not have a price war to the bottom that squeezes out profits.
In this episode of Where the Money Is, health care analysts David Williamson and Michael Douglass discuss the latest decisions coming out of Europe and which big pharma stocks were the biggest winners.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.